NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/17/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization673.7 mln
Float35.67 mln
Earnings Date08/11/2026
1-Year Forecast
25.30
Transformational upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-96.03
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BridgeBio Oncology Therapeutics is a clinical-stage biotech company focused on developing oral drug treatments for several types of cancer, including lung, breast, and colorectal cancers. The company is advancing multiple drug candidates through early-stage clinical trials, each designed to target specific genetic mutations that drive tumor growth. Founded in 2016 and based in South San Francisco, California, BridgeBio Oncology aims to deliver more precise treatment options for cancer patients with limited alternatives.
